RE: Deja Vu Feeling.....17 Jan 2025 10:58
Good morning Krone,
Phase 2 results. This is the interpretation of below. Notice the spin added to the article in your link.
of course that is the benefit of peer review.
Intervention Patients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks.
Main Outcomes and Measures The primary efficacy end point was the proportion of patients achieving 75% or greater improvement in PASI score (PASI 75) at week 12. Secondary efficacy end points included PASI 90 and 100 responses. Safety was also assessed.
Results In total, 259 patients were randomized and received treatment (mean [SD] age, 47 [13] years; 82 women [32%]). At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo. PASI 90 responses were consistent with PASI 75. PASI 100 demonstrated a dose response at all doses, with 17 patients (33%) achieving PASI 100 with zasocitinib, 30 mg. Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters.
Conclusions and Relevance This randomized clinical trial found that potent and selective inhibition of TYK2 with zasocitinib at oral doses of 5 mg or more once daily resulted in greater skin clearance than placebo over 12 weeks.
Trial Registration ClinicalTrials.gov Identifier: NCT04999'
A tad better than Deucravacitinib from memory and of course the all important 12 week Psoriasis Area Severity Index score of 75.
We can therefore deduce it is has greater efficacy but i am very doubtful of acceptable efficacy in treating Ulcerative Colitus as is not dual inhibition ie containing Jak1.
As some know and many dont Jak1 Jak3 inhibitors have very good efficacy but poor safety boxed warning profile. Tofacitinib originally claimed as Jak3 inhibitor but is infact classed now as Jak1 Jak3 with a modest amount Jak2.
Can we do better?
In theory we can as have daul inhibition of Tyk2 Jak1 albeit Breprocitinib Tyk2 Jak1 withdrawn from further development in Psoriasis.
In theory dual inhibition should act quicker.
As Tim has said the Psoriasis market is becoming very competitive, clearly Tim would have have access to these development results.
Sign In
Follow the stocks
